etodolac has been researched along with Adenoma in 2 studies
Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).
etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.
Adenoma: A benign epithelial tumor with a glandular organization.
| Excerpt | Relevance | Reference |
|---|---|---|
| "On the basis of the results of our preliminary trial suggesting that aberrant crypt foci (ACF) could be eradicated by short-term administration of sulindac, in the present study, we explored the feasibility of using ACF as surrogate markers for chemoprevention of colorectal cancer." | 9.15 | Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps. ( Hirayama, M; Kato, J; Kimura, T; Maeda, M; Mori, M; Nagashima, H; Nakano, Y; Niitsu, Y; Nojiri, S; Sato, Y; Sekikawa, H; Sonoda, T; Takahashi, Y; Takayama, T, 2011) |
| "On the basis of the results of our preliminary trial suggesting that aberrant crypt foci (ACF) could be eradicated by short-term administration of sulindac, in the present study, we explored the feasibility of using ACF as surrogate markers for chemoprevention of colorectal cancer." | 5.15 | Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps. ( Hirayama, M; Kato, J; Kimura, T; Maeda, M; Mori, M; Nagashima, H; Nakano, Y; Niitsu, Y; Nojiri, S; Sato, Y; Sekikawa, H; Sonoda, T; Takahashi, Y; Takayama, T, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Takayama, T | 1 |
| Nagashima, H | 1 |
| Maeda, M | 1 |
| Nojiri, S | 1 |
| Hirayama, M | 1 |
| Nakano, Y | 1 |
| Takahashi, Y | 1 |
| Sato, Y | 1 |
| Sekikawa, H | 1 |
| Mori, M | 1 |
| Sonoda, T | 1 |
| Kimura, T | 1 |
| Kato, J | 1 |
| Niitsu, Y | 1 |
| Sano, Y | 1 |
| Kuga, R | 1 |
| Fu, KI | 1 |
| Yoshino, T | 1 |
| Yoshida, S | 1 |
| Ochiai, A | 1 |
| Fujii, T | 1 |
1 trial available for etodolac and Adenoma
| Article | Year |
|---|---|
Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps.
Topics: Aberrant Crypt Foci; Adenoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocol | 2011 |
1 other study available for etodolac and Adenoma
| Article | Year |
|---|---|
Superficially elevated colonic adenoma changed to undetectable configuration on ordinary endoscopy during treatment with preferential cyclooxygenase-2 inhibitor.
Topics: Adenoma; Colonic Neoplasms; Colonoscopy; Cyclooxygenase Inhibitors; Etodolac; Humans | 2003 |